- $343.04bn
- $400.56bn
- $54.32bn
- 80
- 30
- 93
- 75
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 16.55 | ||
PEG Ratio (f) | 0.71 | ||
EPS Growth (f) | 30.12% | ||
Dividend Yield (f) | 3.31% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 50.61 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 19.29 | ||
Price to Sales | 6.24 | ||
EV to EBITDA | 19.26 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 12.27% | ||
Return on Equity | 53.93% | ||
Operating Margin | 22.31% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 33,266 | 45,804 | 56,197 | 58,054 | 54,318 | 55,653.66 | 58,614.21 | 10.65% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -4.92 | -34.67 | +87.55 | +6.38 | -41.65 | +139.45 | +11.18 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.
Directors
- Richard Gonzalez CHM
- Michael Severino PRE
- Robert Michael VCH (51)
- Laura Schumacher VMG (57)
- Timothy Richmond CHO
- Henry Gosebruch EVP (48)
- Azita Saleki - Gerhardt EVP (57)
- Thomas Hudson SVP (59)
- Elaine Sorg SVP (54)
- Jeffrey Stewart SVP (52)
- Carrie Strom SVP (43)
- Brian Durkin VPR (60)
- Glenn Tilton LED (72)
- Robert Alpern IND (70)
- Roxanne Austin IND (60)
- William Burnside IND (69)
- Thomas Freyman IND (66)
- Brett Hart IND (51)
- Edward Liddy IND (75)
- Melody Meyer IND (63)
- Edward Rapp IND (63)
- Rebecca Roberts IND (68)
- Frederick Waddell IND (67)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 10th, 2012
- Public Since
- January 2nd, 2013
- No. of Shareholders
- 42,369
- No. of Employees
- 50,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 1,766,343,745
- Address
- 1 N Waukegan Rd, NORTH CHICAGO, 60064
- Web
- https://www.abbvie.com/
- Phone
- +1 8479327900
- Auditors
- Ernst & Young LLP
Latest News for ABBV
Upcoming Events for ABBV
Dividend For ABBV34.SA - 0.3777 BRL
Dividend For ABBV.NLB - 0.2241 CAD
Dividend For ABBVm.BA - 0.1550 USD
Dividend For ABBV.N - 1.5500 USD
Q3 2024 AbbVie Inc Earnings Release
Q4 2024 AbbVie Inc Earnings Release
Similar to ABBV
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
Catalent
New York Stock Exchange
FAQ
As of Today at 19:29 UTC, shares in Abbvie are trading at $194.21. This share price information is delayed by 15 minutes.
Shares in Abbvie last closed at $194.21 and the price had moved by +26.41% over the past 365 days. In terms of relative price strength the Abbvie share price has underperformed the S&P500 Index by -0.01% over the past year.
The overall consensus recommendation for Abbvie is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Abbvie dividend yield is 3.12% based on the trailing twelve month period.
Last year, Abbvie paid a total dividend of $6.06, and it currently has a trailing dividend yield of 3.12%.Looking ahead, shares in Abbvie are due to go ex-dividend on 2024-10-15 and the next dividend pay date is 2024-11-15.
Abbvie are due to go ex-dividend on 2024-10-15 and the next dividend pay date is 2024-11-15. The historic dividend yield on Abbvie shares is currently 3.12%.
To buy shares in Abbvie you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $194.21, shares in Abbvie had a market capitalisation of $343.04bn.
Here are the trading details for Abbvie:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ABBV
Based on an overall assessment of its quality, value and momentum Abbvie is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abbvie is $197.33. That is 1.61% above the last closing price of $194.21.
Analysts covering Abbvie currently have a consensus Earnings Per Share (EPS) forecast of $10.88 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbvie. Over the past six months, its share price has underperformed the S&P500 Index by -0.07%.
As of the last closing price of $194.21, shares in Abbvie were trading +13.54% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abbvie PE ratio based on its reported earnings over the past 12 months is 16.55. The shares last closed at $194.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abbvie's management team is headed by:
- Richard Gonzalez - CHM
- Michael Severino - PRE
- Robert Michael - VCH
- Laura Schumacher - VMG
- Timothy Richmond - CHO
- Henry Gosebruch - EVP
- Azita Saleki - Gerhardt - EVP
- Thomas Hudson - SVP
- Elaine Sorg - SVP
- Jeffrey Stewart - SVP
- Carrie Strom - SVP
- Brian Durkin - VPR
- Glenn Tilton - LED
- Robert Alpern - IND
- Roxanne Austin - IND
- William Burnside - IND
- Thomas Freyman - IND
- Brett Hart - IND
- Edward Liddy - IND
- Melody Meyer - IND
- Edward Rapp - IND
- Rebecca Roberts - IND
- Frederick Waddell - IND